masitinib tyrosinekinase inhibitor used treatment mast cell tumours animals specifically since introduction november distributed commercial name masivet available europe since second part masitinib studied several human conditions including melanoma multiple myeloma gastrointestinal cancer pancreatic cancer alzheimer disease multiple sclerosis rheumatoid arthritis mastocytosis amyotrophic lateral sclerosis masitinib tyrosine kinase inhibitor inhibits tyrosine kinases enzymes responsible activation many proteins signal transduction cascades specifically masitinib targets receptor tyrosine kinase ckit found overexpressed mutated several types masitinib also additional targets also inhibits platelet derived growth factor receptor pdgfr lymphocytespecific protein tyrosine kinase lck focal adhesion kinase fak fibroblast growth factor receptor well masitinib shown block replication inhibiting main protease masitinib showed reduction viral titers lungs nose mice infected masitinib investigation treatment systemic mastocytosis masipro approval denied eu due concerns reliability study results major changes study european approval masitinib treatment amyotrophic lateral sclerosis alsitek also refused antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikimasitinib